Navigation Links
QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy
Date:7/23/2009

Efficacy and Safety Study in Patients with Moderate to Severe Post-Operative Pain

SYDNEY, Australia and BEDMINSTER, N.J., July 23 /PRNewswire-FirstCall/ -- QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced today the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. Data from this study will serve as a significant predictor of MoxDuo(TM) IV's clinical benefits and provide guidance for the design of further clinical trials leading to submission of an NDA to the US Food and Drug Administration (FDA) within the next three years.

"QRxPharma's goal is to bring to market complementary analgesic options for pain specialists, delivering greater patient tolerability and efficacy than current standards of care. MoxDuo(TM) IV is one of three Dual-Opioid(TM) products that also include immediate-release (IR) and controlled release (CR) oral formulations," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.

QRxPharma's MoxDuo(TM) products are the only combination opioids in commercial development. Extensive clinical studies have shown Dual-Opioids(TM) to provide better pain relief with significantly fewer side effects.

This double blind, active controlled study will determine: (1) whether MoxDuo(TM) IV has fewer opioid-related adverse events than morphine alone at equianalgesic doses and (2) whether the maximum analgesic effect of MoxDuo(TM) IV is superior to morphine alone.

The study is being conducted at the Cologne-Merheim Medical Center, a part of Witten/Herdecke University, and Cologne University Hospital, both in Cologne, Germany.


'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
2. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
3. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
6. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
7. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
8. Medicago initiates work on Swine Flu strain
9. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
10. Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
11. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences Ltd. ... on the treatment of dementia, today announced that ... July 22 at 5:45 p.m. EDT following its ... Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , Chief ...
(Date:7/1/2015)... ... 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker provided ... , The presentation took place on Tuesday, June 16 and provided an update on ... for the treatment of pancreatic cancer. A copy of the company overview can ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... take part in the first half of “Integrative Biotechnology,” an applied biotechnology course ... in summer 2014, this course combines students from both universities and is taught ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... is from Betsy McCaughey, Ph.D., the author of the ... Stimulus Plan."I am requesting that MSNBC and Keith Olbermann ... I, Betsy McCaughey, Ph.D. was paid, directly or indirectly, ... Institute, or Cantel Medical Corp. to write my analysis ...
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... of human viral and other infectious diseases, today reported unaudited ... 31, 2008. At December 31, 2008, Idenix,s cash, cash equivalents ... , ...
... ... Wilmington, DE (Vocus) February 17, 2009 -- DuPont today ... development processes are in compliance with the Excellence Through StewardshipSM ... third-party audit confirms that the company uses the tools of biotechnology ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7DuPont Biotech Stewardship Program Gains External Certification 2DuPont Biotech Stewardship Program Gains External Certification 3
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
(Date:6/17/2015)... Maryland , June 17, 2015 ... mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten    ... Prime Standard: QIA) hat heute in den ... ® für die forensische Analyse ... zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung für ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... than a health hazard according to scientists from The University ... Medicine and Science have discovered powerful antibiotic properties in the ... treatments for multi-drug resistant bacterial infections. They found that the ... were able to kill more than 90 per cent of ...
... photovoltaic (PV) cells world-wide produced a peak amount of electricity ... located in Europe. Similarly to previous years, this shows the ... new solar systems were installed. By the end of 2009, ... installed) was 16 GW, which is about 70% of the ...
... Louis, MO, September 7, 2010 Food manufacturers advertise ... using nutrient claims on the front of packaging. ... of Nutrition Education and Behavior evaluates how consumers are ... claims on consumer perceptions of food products. Findings ...
Cached Biology News:Cockroach brains could be rich stores of new antibiotics 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3Carbohydrate claims can mislead consumers 2Carbohydrate claims can mislead consumers 3
MAb to IgG2 (Fc gamma-2) IgG2 (Fc, gamma-2 epitope)...
... Orange G Dye runs faster than ... standard agarose gels.,Orange G dye migrates ... long. The migration at this size,prevents ... and,conveniently indicates the front of DNA ...
Rabbit anti Xanthine Oxidase Xanthine Oxidase, Bovine Buttermilk...
... without ammonium sulfate are compatible with thermostable ... Taq and AmpliThem™™ DNA polymerases. You can ... in one experiment by adding your own ... PreMixes supplied with the kit. This capability ...
Biology Products: